Pacira BioSciences Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Pacira BioSciences Inc.
- Former names
- Pacira Pharmaceuticals, Inc. Pacira Inc Blue Acquisition Corp
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Brisbane
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- PCRX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001396814
- EIN
- 51-0619477
Board of directors
-
Abraham Ceesay · DirectorSince 2023
-
Alethia Young · DirectorSince 2023
-
Christopher Christie · DirectorSince 2023
-
David M. Stack · Director · CEO and ChairmanSince 2023
-
Frank D. Lee · Director · Chief Executive OfficerSince 2024
-
Gary W. Pace · DirectorSince 2023
-
Laura Brege · DirectorSince 2023
-
Marcelo Bigal · DirectorSince 2023
-
Mark A. Kronenfeld · DirectorSince 2023
-
Mark Froimson · DirectorSince 2023
-
Michael J. Yang · DirectorSince 2023
-
Paul J. Hastings · DirectorSince 2023
-
Samit Hirawat · DirectorSince 2026
-
Thomas G. Wiggans · DirectorSince 2026
Chief executives
Frank D. Lee
· Chief Executive Officer
Since January 2024
David M. Stack
· CEO and Chairman
Until January 2024
· Former
Director election results
Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
76.5%
-
85.6%
-
85.9%
Board connections
8 of this board's directors also sit on 14 other boards.
- via Laura Brege
- via Thomas G. Wiggans
- via Frank D. Lee
- via Frank D. Lee
- via Gary W. Pace
- via Abraham Ceesay
- via Laura Brege
- via Michael J. Yang
- via Thomas G. Wiggans
- via Laura Brege
- via Paul J. Hastings
- via Alethia Young
- via Abraham Ceesay
- via Paul J. Hastings
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $2,532,124
- 16 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 17, 2026 | SLONIN JONATHAN Officer (Chief Medical Officer) | Open-market sale | −3,040 | $23.23 | $70,619 |
| Jun 11, 2026 | RIKER LAUREN Officer (Senior Vice President, Finance) | Open-market sale | −6,115 | $23.50 | $143,703 |
| Jun 10, 2026 | Samit Hirawat Director | Grant or award | +6,405 | — | — |
| Jun 10, 2026 | Christopher Christie Director | Grant or award | +6,405 | — | — |
| Jun 10, 2026 | Alethia Young Director | Grant or award | +6,405 | — | — |
| Jun 10, 2026 | Michael J. Yang Director | Grant or award | +6,405 | — | — |
| Jun 10, 2026 | Marcelo Bigal Director | Grant or award | +6,405 | — | — |
| Jun 10, 2026 | Mark Froimson Director | Grant or award | +6,405 | — | — |
| Jun 10, 2026 | Laura Brege Director | Grant or award | +6,405 | — | — |
| Jun 4, 2026 | WILLIAMS KRISTEN Officer (Chief Administrative Officer) | Open-market sale | −10,259 | $22.27 | $228,468 |
| Jun 3, 2026 | RIKER LAUREN Officer (Senior Vice President, Finance) | Shares withheld for tax | −3,187 | $22.32 | $71,134 |
| Jun 3, 2026 | SLONIN JONATHAN Officer (Chief Medical Officer) | Shares withheld for tax | −4,728 | $22.32 | $105,529 |
| Jun 3, 2026 | WILLIAMS KRISTEN Officer (Chief Administrative Officer) | Shares withheld for tax | −8,528 | $22.32 | $190,345 |
| Apr 23, 2026 | Cross Shawn Officer (Chief Financial Officer) | Option exercise | +12,941 | $16.45 | $212,879 |
| Apr 23, 2026 | Cross Shawn Officer (Chief Financial Officer) | Open-market sale | −12,941 | $25.16 | $325,596 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.